KCN1, a Novel Synthetic Sulfonamide Anticancer Agent: In Vitro and In Vivo Anti-Pancreatic Cancer Activities and Preclinical Pharmacology

Wei Wang; Lin Ao; Elizabeth R. Rayburn; Hongxia Xu; Xiangrong Zhang; Xu Zhang; Subhasree Ashok Nag; Xuming Wu; Ming-Hai Wang; Hui Wang; Erwin G. Van Meir; Ruiwen Zhang

doi:10.1371/journal.pone.0044883

Loading metrics

Open Access

Peer-reviewed

Research Article

KCN1, a Novel Synthetic Sulfonamide Anticancer Agent: In Vitro and In Vivo Anti-Pancreatic Cancer Activities and Preclinical Pharmacology

Wei Wang ,

Contributed equally to this work with: Wei Wang, Lin Ao

Affiliations Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas, United States of America, Cancer Biology Center, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas, United States of America, Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America
⨯
Lin Ao ,

Contributed equally to this work with: Wei Wang, Lin Ao

Affiliations Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas, United States of America, Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America
⨯
Elizabeth R. Rayburn,

Affiliation Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America
⨯
Hongxia Xu,

Affiliations Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas, United States of America, Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America
⨯
Xiangrong Zhang,

Affiliations Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas, United States of America, Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America
⨯
Xu Zhang,

Affiliations Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas, United States of America, Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America
⨯
Subhasree Ashok Nag,

Affiliation Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas, United States of America
⨯
Xuming Wu,

Affiliations Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas, United States of America, Nantong Cancer Hospital, Nantong University, Nantong, China
⨯
Ming-Hai Wang,

Affiliations Cancer Biology Center, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas, United States of America, Department of Biomedical Sciences, Texas Tech University Health Sciences Center, Amarillo, Texas, United States of America
⨯
Hui Wang,

Affiliation Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China
⨯
Erwin G. Van Meir ,

* E-mail: evanmei@emory.edu (EGVM); ruiwen.zhang@ttuhsc.edu (RZ)

Affiliations Department of Neurosurgery, Emory University School of Medicine, Atlanta, Georgia, United States of America, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, United States of America, Winship Cancer Institute, Emory University, Atlanta, Georgia, United States of America
⨯
Ruiwen Zhang

* E-mail: evanmei@emory.edu (EGVM); ruiwen.zhang@ttuhsc.edu (RZ)

Affiliations Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas, United States of America, Cancer Biology Center, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas, United States of America, Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America
⨯

KCN1, a Novel Synthetic Sulfonamide Anticancer Agent: In Vitro and In Vivo Anti-Pancreatic Cancer Activities and Preclinical Pharmacology

Wei Wang,
Lin Ao,
Elizabeth R. Rayburn,
Hongxia Xu,
Xiangrong Zhang,
Xu Zhang,
Subhasree Ashok Nag,
Xuming Wu,
Ming-Hai Wang,
Hui Wang

Published: September 13, 2012
https://doi.org/10.1371/journal.pone.0044883

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Pancreatic cancer
Is the Subject Area "Pancreatic cancer" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Cell cycle and cell division
Is the Subject Area "Cell cycle and cell division" applicable to this article?

Thanks for your feedback.
Apoptosis
Is the Subject Area "Apoptosis" applicable to this article?

Thanks for your feedback.
Genetically modified animals
Is the Subject Area "Genetically modified animals" applicable to this article?

Thanks for your feedback.
Cyclins
Is the Subject Area "Cyclins" applicable to this article?

Thanks for your feedback.
Mouse models
Is the Subject Area "Mouse models" applicable to this article?

Thanks for your feedback.
Plasma proteins
Is the Subject Area "Plasma proteins" applicable to this article?

Thanks for your feedback.